Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB-IIA non-small cell lung cancer
Open Access
- 1 June 2004
- journal article
- research article
- Published by BMJ in Journal of Clinical Pathology
- Vol. 57 (6), 591-597
- https://doi.org/10.1136/jcp.2003.013508
Abstract
Aims: To evaluate the prognostic impact of tumour angiogenesis assessed by vascular endothelial growth factor (VEGF), microvessel density (MVD), and tumour vessel invasion in patients who had undergone radical resection for stage IB–IIA non-small cell lung cancer (NSCLC). Methods: Fifty one patients (42 men, nine women; mean age, 62.3 years; SD, 6.9) undergoing complete surgical resection (35 lobectomy, 16 pneumonectomy) of pathological stage IB (n = 43) and IIA (n = 8) NSCLC were evaluated retrospectively. No patient underwent postoperative chemotherapy or neoadjuvant treatment. Tumour specimens were stained for VEGF and specific MVD markers: CD31, CD34, and CD105. Results: VEGF expression significantly correlated with high CD105 expression (p < 0.0001) and tumour vessel invasion (p = 0.04). Univariate analysis showed that those patients with VEGF overexpression (p = 0.0029), high MVD by CD34 (p = 0.0081), high MVD by CD105 (p = 0.0261), and tumour vessel invasion (p = 0.0245) have a shorter overall survival. Furthermore, multivariate Cox regression analysis showed that MVD by CD34 (p = 0.007), tumour vessel invasion (p = 0.024), and VEGF expression (p = 0.042) were significant predictive factors for overall survival. Finally, the presence of both risk factors, tumour vessel invasion and MVD by CD34, was highly predictive of poor outcome (odds ratio, 3.4; 95% confidence interval, 1.7 to 6.5; p = 0.0002). Conclusions: High MVD by CD34 and tumour vessel invasion are more closely related to poor survival than the other neoangiogenetic factors in stage IB–IIA NSCLC. This may be because these factors are more closely related to the metastatic process.Keywords
This publication has 30 references indexed in Scilit:
- Vascular Endothelial Growth Factor Expression in Stage I Non-Small Cell Lung Cancer Correlates With Neoangiogenesis and a Poor PrognosisAnnals of Surgical Oncology, 2001
- Increased vascular endothelial growth factor and vascular endothelial growth factor–c and decreased nm23 expression associated with microdissemination in the lymph nodes in stage i non–small cell lung cancerThe Journal of Thoracic and Cardiovascular Surgery, 2000
- The clinical significance of hepatocyte growth factor for non–small cell lung cancerThe Annals of Thoracic Surgery, 1998
- Vascular endothelial growth factor expression in non-small-cell lung cancer: Prognostic significance in squamous cell carcinomaThe Journal of Thoracic and Cardiovascular Surgery, 1998
- Tumor Angiogenesis as a Prognostic Marker in Operable Non–Small Cell Lung CancerThe Annals of Thoracic Surgery, 1998
- Angiogenesis As A Predictor Of Survival After Surgical Resection For Stage I Non-Small-Cell Lung CancerThe Journal of Thoracic and Cardiovascular Surgery, 1998
- Potential role ofbcl-2 as a suppressor of tumour angiogenesis in non-small-cell lung cancerInternational Journal of Cancer, 1997
- Relation of neovascularisation to metastasis of non-small-cell lung cancerThe Lancet, 1992
- Tumor Angiogenesis and Metastasis — Correlation in Invasive Breast CarcinomaNew England Journal of Medicine, 1991
- Computed Tomography for Evaluation of Mediastinal Lymph Nodes in Lung Cancer: Correlation with Surgical StagingThe Annals of Thoracic Surgery, 1984